IP Library Granted Patent US 8,097,706
Granted Patent B2
US 8,097,706 · App. 12/742,367 · Granted Jan 17, 2012

Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,706
App. No.
12/742,367
Granted
Jan 17, 2012
Kind
B2
Abstract

The present invention relates to a method for preparing capecitabine and a method for preparing a β-anomer-rich trialkyl carbonate compound used therein, and a highly pure capecitabine can be efficiently prepared with a high yield by the method of the present invention using the β-anomer-rich trialkyl carbonate compound as an intermediate.

Claims (18)

1. A method for preparing capecitabine of formula 1, comprising the steps of:

(1) hydrolyzing a methylacetonide compound of formula 2 to obtain a triol compound of formula 3;

(2) reacting the compound of formula 3 with an haloalkyl formate of formula 4 in the presence of mixture of pyridine and triethylamine to obtain a β-anomer-rich trialkyl carbonate compound of formula 5;

(3) conducting a glycosylation of the compound of formula 5 using 5-fluorocytosine in the presence of an acid to obtain a dialkoxycarbonyl cytidine compound of formula 6;

(4) performing carbamoylation of the compound of formula 6 using n-pentyl chloroformate to obtain a carbamoylcytidine compound of formula 7; and

(5) deprotecting the carbonate hydroxy protecting groups of the compound of formula 7:

wherein,

X is chloro, bromo or iodo; and

R is methyl or ethyl.

2. A method for preparing a trialkyl carbonate compound of formula 5, comprising the steps of:

(1) hydrolyzing a methylacetonide compound of formula 2 to obtain a triol compound of formula 3; and

(2) letting the compound of formula 3 react with a haloalkyl formate of formula 4 in the presence of a mixture of pyridine and triethylamine to obtain a β-anomer-rich trialkyl carbonate of formula 5:

wherein, X and R have the same meanings as defined in claim 1 .

3. The method of claim 2 , wherein pyridine is employed in an amount ranging from 1 to 2 equivalents based on triethylamine.

4. The method of claim 2 , wherein the mixture of pyridine and triethylamine is employed in an amount ranging from 4 to 10 equivalents based on the compound of formula 3.

5. The method of claim 2 , wherein the reaction in step (2) is conducted at a temperature of −50 to −30° C.

6. The method of claim 1 , wherein the acid employed in step (3) is ethylaluminumdichloride, methylaluminumdichloride, SnCl 4 , trimethylsilyl trifluoromethanesulfonic acid or trifluoromethanesulfonate.

7. The method of claim 6 , wherein the acid is employed in an amount ranging from 0.5 to 3 equivalents based on the compound of formula 5.

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
CHANGE OF NAME Recorded Jan 7, 2011
From: HANMI PHARM. CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025599/0842 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2010
From: LEE, JAEHEON; PARK, GHA-SEUNG; YANG, WEON KI; KIM, JIN HEE; PARK, CHEOL HYUN; AN, YONG-HOON; LEE, YOON JU; CHANG, YOUNG-KIL; LEE, GWAN SUN
To: HANMI PHARM. CO., LTD.
Reel/Frame 024367/0782 →